Abstracts Archive - Page 2039 of 2605 - ACR Meeting Abstracts

Abstract Number: 2899 • 2014 ACR/ARHP Annual Meeting
High Dose Aspirin for Treating Kawasaki Disease – Outdated Myth or Effective Aid?
Gil Amarilyo¹, Yael Koren², Dafna Brik Simon³, Maskit Bar-Meir⁴, Hilla Bahat⁵, Mona Hanna Helou⁶, Amir Mendelson⁷, Yackov Berkun⁸, Eli Eisenstein⁹, Yonatan butbul Aviel¹⁰, Galia Barkai¹¹, Yoav Bolkier¹¹, Shai Padeh¹¹, Philip J. Hashkes¹², Riva Brik¹⁰, Liora Harel¹ and Yosef Uziel¹³, ¹Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ⁴Infectious Diseases, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatrics, Assaf Harofeh Medical Center, Zerifin, Israel, ⁶Pediatrics B Department, Rambam Medical Center, Haifa, Israel, ⁷Pediatric Rheumatology, Meir Medical Center, Kfar Saba, Israel, ⁸Pediatrics and Pediatric Rheumatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁹Dept of Pediatrics, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, ¹¹Sheba Medical Center, Tel-Hashomer, Israel, ¹²Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ¹³Pediatric Rheumatology Unit , Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Kawasaki disease (KD) is generally treated with intravenous immunoglobulin (IVIG) together with high anti-inflammatory doses of acetyl salicylic acid (ASA), which is subsequently switched…
Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting
Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Beverley Almeida¹, Raquel Campanilho-Marques², Katie Arnold², Lucy R. Wedderburn^3,4, Clarissa A Pilkington⁵ and Kiran Nistala⁶, ¹Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁵Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
Abstract Number: 2901 • 2014 ACR/ARHP Annual Meeting
Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis
Gabriele Simonini¹, Claudia Bracaglia², Marco Cattalini³, Andrea Taddio⁴, Alice Brambilla⁵, Cinzia DeLibero⁶, Denise Pires Marafon⁷, Roberto Caputo⁶ and Rolando Cimaz¹, ¹Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Pediatric Clinic, Spedali Civili di Brescia and University of Brescia, Pediatric Immunology and Rheumatology Unit, Brescia, Italy, ⁴Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy, ⁵Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ⁶Ophthalmology Unit, Anna Meyer Children's Hospital, Florence, Italy, ⁷Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
Background/Purpose Information regarding the natural clinical history of a child on systemic treatment due to auto-immune chronic uveitis would be helpful in driving duration therapy.…
Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting
The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care
Kirsten Minden¹, Jens Klotsche², Martina Niewerth², Angela Zink³ and Gerd Horneff⁴, ¹Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting
Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Kimberly Morishita¹, Susanne Benseler², Rae S.M. Yeung³, Thomas Mason II⁴, Dawn Wahezi⁵, Kenneth N. Schikler⁶, Erica F. Lawson⁷, Susan Nielsen⁸, Sirirat Charuvanij⁹, Paul Dancey¹⁰, Susan Shenoi¹¹, Linda Wagner-Weiner¹², Angelyne Sarmiento¹, David A. Cabral¹³ and For the PedVas Initiative¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, ⁷Pediatrics, University of California, San Francisco, San Francisco, CA, ⁸Pediatric rheumatology, Rigshospitalet, Copenhagen, Denmark, ⁹Pediatrics, Siriraj Hospital, Bangkok, Thailand, ¹⁰Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹¹Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, ¹²Pediatric Rheumatology, University of Chicago Hospital, Chicago, IL, ¹³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood AAV is rare and outcome studies are limited. The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…
Abstract Number: 2904 • 2014 ACR/ARHP Annual Meeting
Clinical and Radiological Features of Down’s Arthropathy
Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland
Background/Purpose The ‘Arthropathy of Down syndrome’ was first described in 1984. Three decades on we still have limited literature on the clinical & radiological features…
Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting
The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice
Jennifer L. Auger¹, Brianna J. Engelson², Yaya Wang³, Erik J. Peterson⁴ and Bryce A. Binstadt⁵, ¹Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ²Pediatrics, University of Minnesota, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
Abstract Number: 2906 • 2014 ACR/ARHP Annual Meeting
Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis
Shuang Liu¹, Takeshi Kiyoi², Shohei Watanabe³ and Kazutaka Maeyama¹, ¹Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, ²Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, ³Japan Community Health Care Organization Uwajima Hospital, Ehime, Japan
Background/Purpose: In recent years, one widespread and potentially important Ca2+ channel, store-operated Ca2+-release-activated Ca2+ (CRAC) channel is raised in drug discovery for rheumatoid arthritis (RA).…
Abstract Number: 2907 • 2014 ACR/ARHP Annual Meeting
Loss of microRNA-146a Exacerbates Inflammatory Arthritis
Victoria Saferding¹, Antonia Puchner², Eliana Goncalvesalves³, Birgit Niederreiter⁴, Silvia Hayer⁴, Gernot Schabbauer⁵, Marije Koenders⁶, Josef Smolen¹, Kurt Redlich³ and Stephan Blueml³, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, ⁶Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: MicroRNA (MiR-) 146a is a key regulator of the innate immune response and has also been shown to suppress cancer development in myeloid cells.…
Abstract Number: 2908 • 2014 ACR/ARHP Annual Meeting
Flip Deficiency in Dendritic Cells Promotes Spontaneous Arthritis Mediated By Reduced Treg and Increased Autoreactive CD4⁺t Cells
Qiquan Huang¹, Harris R. Perlman², Robert Birkett³, Renee E. Doyle⁴, Deyu Fang⁵, G Kenneth.Haines⁶, William H. Robinson⁷, Syamal K. Datta⁸, Hyewon Phee⁹ and Richard M. Pope¹⁰, ¹Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Mount Sinai Hospital School of Medicine, New York, New York, NY, ⁷VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁸Rheumatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose Flip (CFLAR) has been identified as a rheumatoid arthritis (RA) risk allele and is important in preventing death receptor mediated apoptosis of dendritic cells…
Abstract Number: 2909 • 2014 ACR/ARHP Annual Meeting
Tolerogenic Splenic IDO+ Dendritic Cells from the Mice Treated with Induced-Treg Cells Could Suppress Collagen-Induced Arthritis
Jie Yang¹, Huahua Fan² and Hejian Zou¹, ¹Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China, Shanghai, China, ²Blood Engineering Laboratory, Shanghai Blood Center, Shanghai 200051, China, Shanghai, China
Background/Purpose As well known, Foxp3+ regulatory T cells play a crucial role in maintaining immune tolerance. It was reported that TGF-β-induced Tregs (iTregs) could retain…
Abstract Number: 2910 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice
Keisuke Nishimura¹, Jun Saegusa¹, Fumichika Matsuki², Kengo Akashi¹, Goichi Kageyama¹ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are characterized by the co-expression of Gr1 and CD11b in mice. MDSCs suppress…
Abstract Number: 2911 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?
Tuulikki Sokka¹, Hannu Kautiainen², Tuomas Rannio³, Juha Asikainen¹ and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Medcare Oy, Äänekoski, Finland, ³Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Early vs. delayed referral/start of therapy within 3-4 months has been shown beneficial for outcomes in rheumatoid arthritis (RA) (Lard et al. AM J…
Abstract Number: 2912 • 2014 ACR/ARHP Annual Meeting
Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program
Walter P. Maksymowych^1,2, M. Østergaard³, O Elkayam⁴, R Landewé⁵, J Homik⁶, C Thorne⁷, M Backhaus⁸, S Shaikh⁹, G Boire¹⁰, M Larche¹¹, B Combe¹², T Schaeverbeke¹³, A Saraux¹⁴, G Ferraccioli¹⁵, M Dougados¹⁶, C Barnabe¹⁷, M Govoni¹⁸, PP Tak¹⁹, D. van Schaardenburg²⁰, D van der Heijde²¹, R Dadashova², E Hutchings², J Paschke² and Oliver FitzGerald²², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²CaRE Arthritis, Edmonton, AB, Canada, ³Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ⁹Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, ¹⁰CHUS-Sherbrooke University, Sherbrooke, QC, Canada, ¹¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ¹²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴CHU Brest and EA 2216, UBO, Brest, France, ¹⁵Catholic University of The Sacred Heart, Rome, Italy, ¹⁶Hopital Cochin, Paris, France, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Universita di Ferrara, Ferrara, Italy, ¹⁹Academic Medical Center, Amsterdam, Netherlands, ²⁰Jan van Breemen Research Institute, Amsterdam, Netherlands, ²¹Leiden University Medical Center, Leiden, Netherlands, ²²St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose . There is limited data on adherence to treat-to-target (T2T) strategies in RA in real world-practice and the impact of failure to adopt this…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].